Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | TEK | Q02763 | 3/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17661802 | 0.89 | MET (0.42) | METKDRAURKATEKAURKB | |
| SCHEMBL14949238 | 0.81 | KDR (0.49) | METKDRAURKATEKAURKB | |
| SCHEMBL22435917 | 0.73 | KDR (0.57) | METKDRAURKATEKAURKB | |
| SCHEMBL14949214 | 0.72 | KDR (0.49) | METKDRAURKATEKAURKB | |
| SCHEMBL25466495 | 0.71 | FGFR2 (0.60) | METKDRAURKATEKAURKB | |
| SCHEMBL12336254 | 0.71 | GSK3A (0.50) | METKDRPDGFRA | |
| SCHEMBL14949392 | 0.70 | KDR (0.49) | METKDRAURKATEKAURKB | |
| SCHEMBL14949221 | 0.70 | FGFR2 (0.49) | METKDRAURKATEKAURKB | |
| SCHEMBL17658742 | 0.69 | PDGFRB (0.42) | PDGFRBFLT3PDGFRAHPGDS | |
| SCHEMBL22435918 | 0.68 | FGFR2 (0.62) | METKDRAURKATEKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | MET 770/4885KDR 533/4885AURKA 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.